Literature DB >> 9744674

Temporal trends in reasons for and result of HIV-testing among women in Rome, Italy.

V Puro1, C D'Ubaldo, M S Aloisi, L Sherr, G Ippolito.   

Abstract

To describe the trend in the reasons for and result of women's HIV testing, systematic data was gathered for 11,523 consecutive women during pre-and post-test visits at a major counseling and testing (CT) site of Rome, Italy, June 1985-July 1996. The number of tested women and the proportion of female clients attending the CT site significantly increased during the study period (p < 0.001), mostly because of reported sexual risk or when triggered by pregnancy. A significant increasing trend in the proportion of women who had one prior test (30% overall) was observed in all groups, apart from IDU. Newly diagnosed HIV infections were 319 (2.8%). The HIV prevalence was 27% in 1985-1987, when 66.7% of cases were IDUs, and decreased to 1.3% in 1994-1996, when 53.7% of cases were women reporting HIV infected partners. The findings suggest that information on the potential risk of HIV transmission has permeated the female population. The shift of newly diagnosed infections from IDUs towards women reporting sexual exposure, suggests the need for targeting preventive efforts to these population groups. Underlying reasons for multiple testing need further analysis.

Entities:  

Mesh:

Year:  1998        PMID: 9744674     DOI: 10.1023/a:1007422714701

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  14 in total

1.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

Review 2.  The third wave: HIV infection among heterosexuals in the United States and Europe.

Authors:  H W Haverkos; T C Quinn
Journal:  Int J STD AIDS       Date:  1995 Jul-Aug       Impact factor: 1.359

3.  Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1987-08-14       Impact factor: 17.586

Review 4.  Global burden of the HIV pandemic.

Authors:  T C Quinn
Journal:  Lancet       Date:  1996-07-13       Impact factor: 79.321

Review 5.  The acceptability of voluntary HIV antibody testing in the United States: a decade of lessons learned.

Authors:  K L Irwin; R O Valdiserri; S D Holmberg
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

6.  A national surveillance system for newly acquired HIV infection in Australia. National HIV Surveillance Committee.

Authors:  A M McDonald; D M Gertig; N Crofts; J M Kaldor
Journal:  Am J Public Health       Date:  1994-12       Impact factor: 9.308

7.  A study of clients returning for counseling after HIV testing: implications for improving rates of return.

Authors:  R O Valdiserri; M Moore; A R Gerber; C H Campbell; B A Dillon; G R West
Journal:  Public Health Rep       Date:  1993 Jan-Feb       Impact factor: 2.792

8.  Limited effects of HIV counseling and testing for women. A prospective study of behavioral and psychological consequences.

Authors:  J R Ickovics; A C Morrill; S E Beren; U Walsh; J Rodin
Journal:  JAMA       Date:  1994-08-10       Impact factor: 56.272

9.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

10.  HIV media campaigns and HIV-1 testing trends at London genitourinary medicine clinic, 1985-1993.

Authors:  R Griffith; S Mandalia; E J Beck; C Kenny; R P Watkins; E Claydon; J R Harris
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.